If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
253
results.
Updated on
07/05/2026 [07:05:00]
Results 200 to 225 of 253
Absstract of: US20260108474A1
A PAMAM-based protein degradation system and a method of preparation and use thereof are provided. The protein degradation system comprises: a silica nanoparticle core; and a poly(amidoamine) dendrimer (PAMAM) layer coated on a surface of the silica nanoparticle, wherein the PAMAM layer is linked via amide bonds to three small-molecule ligands: MDM2 protein ligand Idasanutlin, GLUT1 protein ligand Lavendustin B and E3 ubiquitin ligase ligand Thalidomide-NH—CH2—COOH. The nanoparticle protein degradation system cooperatively degrades MDM2 protein and GLUT1 protein. This cooperative degradation strategy not only effectively suppresses proliferation and energy metabolism of tumor cells, but also significantly enhances the stability of p53 protein. By restoring the normal function of p53 protein, tumor cell growth is further inhibited, providing a new strategy for cancer therapy.
Absstract of: US20260109976A1
0000 Provided herein are heterologous engineered mRNA molecules; and methods of making and using said synthetic engineered mRNAs to increase expression profiles.
Absstract of: WO2026085498A1
The present disclosure provides compositions and methods for enhancing gene editing. In some aspects, the compositions and methods are used prevent the progression or treat diseases such as osteoarthritis and other joint disorders that are characterized by an inflammatory component.
Absstract of: WO2026085291A1
Disclosed herein are metabolizable binary gold supraclusters, which, in some implementations, comprise cationic gold nanoclusters laden with a therapeutic nucleic acid, such as a small interfering RNA (siRNA), and are intertwined through bioresponsive crosslinkers within a hydrophilic polymer matrix. Also provided herein are uses of the supraclusters, e.g., in treatment of diseases such as cancers.
Absstract of: WO2026085500A1
Provided herein are compositions and methods for ablating intracellular signaling through specific cell surface receptors as means of treatment for various conditions of a pro-inflammatory character. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritides and to treat osteoarthritis and other arthritides in a mammalian joint. In some aspects, the compositions and method are for treating or preventing localized nociception, inflammation, degeneration, or morphological changes associated with back or spine conditions or disorders.
Absstract of: US20260108656A1
The present invention relates to a levan-catechol composite, and a tissue adhesion composition and nanocluster, including same. In particular, the levan-catechol composite is prepared by the conjugation of levan and catechol and is applicable, by hydrogelation or nanoclustering thereof, for use in tissue adhesion in wet environments, wound healing, hemostasis, or drug delivery.
Absstract of: US20260109984A1
0000 Therapeutic methods, systems, and compositions for treating a patient suffering from hemoglobinopathy include treating the patient to increase expression of noncoding RNA activated by DNA damage (NORAD). Overexpression of NORAD long non-coding RNA leads to an increase in fetal hemoglobin expression. The hemoglobinopathy may be β-thalassemia or sickle cell disease.
Absstract of: US20260108472A1
0000 Disclosed are methods and compositions for restoring Cyr61 in bone tissue. In certain aspects, the compositions comprise a recombinant Cyr61 carried in carbon nanotubes. The compositions may be used for various methods including restoring Cyr61 expression in bone, increasing bone density, or treating a bone disease in a patient.
Absstract of: WO2026083241A1
The present disclosure provides ionizable lipids that are particularly beneficial in formulations of lipid nanoparticles providing advantageous improvements in the delivery of nucleic acids to hepatic stellate cells with enhanced efficiency. The ionizable lipids are N,N-substituted hydroxylamine ester compound. The disclosure also provides lipid nanoparticles, pharmaceutical compositions, and methods including the provided ionizable lipids.
Absstract of: WO2026083169A2
The present invention relates to natural nanocarriers or nanoparticles with biocompatible, biodegradable, hypoallergenic, environmentally and physiologically acceptable properties. More in particular, it can be stated that the present invention relates to natural biopolymer nanocarriers, nanoparticles or nano-spheres with biocompatible, biodegradable, environmentally and physiologically acceptable properties as vehicles for physiological and environmentally safe delivery of active ingredients. The present invention also relates to nanoparticle compositions, methods of making the nanoparticles and nanoparticles compositions, as well as uses thereof.
Absstract of: WO2026082030A1
Provided in the present invention is an ionizable lipid compound. Specifically, the present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, or stereoisomer thereof. Further provided in the present invention are a nanoparticle pharmaceutical composition containing the compound, and the use of the compound and composition thereof in the delivery of nucleic acids.
Absstract of: US20260108537A1
This disclosure describes a cannabinoid-based nanoplatform for treating shingles, designed to enhance bioavailability and controlled release of active ingredients. The composition includes cannabinoids like cannabidiol (CBD) and cannabigerol (CBG), alongside flavonoids, polyphenols, and alkaloids, in oral and topical formulations. The oral capsule combines cannabinoids with polyphenols and flavonoids to provide systemic anti-inflammatory, antiviral, and neuroprotective effects, particularly for nerve pain and inflammation, including postherpetic neuralgia. The topical cream includes cannabinoids, capsaicin, and aloe vera, offering localized relief from pain, itching, and rash. The method targets both systemic and localized symptoms during the acute phase of shingles, aiming to inhibit varicella-zoster virus replication, disrupt viral assembly, and prevent viral release, while also providing immune modulation and anti-inflammatory benefits. The nanoplatform uses nano-emulsification techniques, producing particles smaller than 200 nm to ensure optimal delivery and therapeutic efficacy, offering comprehensive relief for shingles symptoms.
Absstract of: US20260108627A1
Compositions and methods are described herein for treating subjects having hypercholesterolemia and/or cardiovascular disease.
Absstract of: US20260108503A1
Micelle compositions comprising a hedgehog pathway inhibitor and their use in treating skin diseases, conditions, or disorders, such as skin cancers, including basal cell carcinoma, are disclosed.
Absstract of: AU2026202508A1
Methods are disclosed for treating a subject with a disorder, such as, but not limited to, a) fibrosis of an organ or tissue; b) solid organ transplant rejection; or c) a cardiac disease that is not myocardial infarction or myocardial ischemia. These methods include selecting a subject having or at risk of having the disorder, and administering to the subject a therapeutically effective amount of isolated nanovesicles derived from an extracellular matrix, wherein the nanovesicles contain interleukin (IL)-33 and comprise lysyl oxidase, and wherein the nanovesicles a) do not express CD63 or CD81, or b) are CD63loCD81lo. In additional embodiments, methods are disclosed for increasing myoblast differentiation. pr p r
Absstract of: WO2026081389A1
The present invention relates to the field of pharmaceutical technology, and in particular, to a daptomycin nano-FORMULATION, a method for preparing same, and use thereof. The method comprises: A, encapsulating daptomycin with a copolymer poly(lactic-co-glycolic acid) to give a nanoparticle (NP); and B, sonicating a cell membrane vesicle overexpressing RANK and the nanoparticle (NP) in a water bath for 3 min, and then sequentially extruding the mixture through polycarbonate membranes of 800 nm, 400 nm, and 200 nm to give the daptomycin nano-formulation. The weight ratio of the membrane protein to PLGA is 0.25. By the method of the present invention, a daptomycin nano-formulation targeting rheumatoid arthritis is successfully prepared. The daptomycin nano-formulation prepared by the present invention has good stability. The daptomycin nano-formulation of the present invention has good therapeutic effects against RA.
Absstract of: US20260108633A1
0000 An application for the EGT-AuNPs in preparing contrast agents and/or antioxidants is provided, where the EGT-AuNPs include gold nanoparticles (AuNPs), the AuNPs are connected to L-ergothioneine (EGT) by gold-sulfur bonds, and the antioxidants include medicines for preventing and/or treating acute kidney injury (AKI). EGT-AuNPs with antioxidant activity are designed and synthesized through the combination of the higher imaging contrast of gold and the antioxidant natural product EGT, and they are ultra-small AuNPs, which achieve the combination of CT imaging and antioxidant effects, and are suitable for renal imaging, particularly for the early diagnosis and treatment of AKI, realizing the integration of diagnosis and treatment, circumventing the toxicity of contrast agents present in the conventional nanomaterials, lowering the serum creatinine and urea nitrogen levels, and reducing the degree of renal tubular damage.
Absstract of: WO2026082012A1
The present invention provides a drug-loaded nanoparticle composition suitable for drug delivery in vivo, wherein the drug-loaded nanoparticle composition is formed in the form of a non-covalent bond and comprises an active ingredient, cyclodextrin, and albumin. Drug-loaded nanoparticles or the composition thereof in the present invention are stable in a solution state, avoiding cumbersome operations of reconstitution and redissolution. Compared with a known freeze-dried powder of nanoparticles containing albumin, the nanoparticles in the present invention have a particle size of less than 150 nm, can remain stable for at least 7 days or more without change, and can be predicted to be stable for a long time.
Absstract of: WO2026082183A1
Disclosed in the present invention is a lyoprotectant for nucleic acid-lipid nanoparticles. The lyoprotectant of the present invention is formed by combining sucrose or trehalose with polyvinylpyrrolidone in a specific ratio, and provides a good lyoprotective effect for the nucleic acid-lipid nanoparticles, ensuring that there is no significant difference in particle size, uniformity, encapsulation efficiency, nucleic acid integrity, and expression performance of the nucleic acid-lipid nanoparticles before and after lyophilization. Furthermore, by adjusting the salt concentration in a mixed solution of the nucleic acid-lipid nanoparticles and the lyoprotectant, the lyoprotective effect on the nucleic acid-lipid nanoparticles is further improved, so that the performance of lyophilized nucleic acid-lipid nanoparticles is closer to that before lyophilization.
Absstract of: US20260108475A1
Methods for inserting a targeting moiety (such as an antigen-binding protein moiety, a fragment antigen-binding moiety, or the like) into a lipid nanoparticle and compositions resulting from such methods are provided. The methods generally utilize a reaction that forms targeted nanoparticles by combining a targeting moiety and a lipid nanoparticle. A quenching operation is then provided by cooling the reaction to a temperature that stops the insertion of the targeting moiety. The reaction substantially preserves the integrity of a nucleic acid cargo (such as an mRNA encoding a VHH binding molecule).
Absstract of: WO2026085319A1
The present disclosure relates, in one aspect, to degradable ionizable lipid compounds of formula (I). In another aspect, the disclosure relates to lipid nanoparticles (LNPs) comprising at least one ionizable lipid of formula (I). In another aspect, the disclosure provides methods of the LNPs of the disclosure for splenic delivery of therapeutic cargo.
Absstract of: WO2026084314A1
The present invention relates to: lipid nanoparticles with improved genetic material delivery efficiency through the regulation of an extracellular matrix and pH control of intracellular organelles; and use thereof. A composition for delivering a genetic material, according to the present invention, comprises lipid nanoparticles and a proton pump inhibitor, whereby the genetic material can be effectively delivered by overcoming various intracellular and extracellular barriers and the limitations of existing delivery systems.
Absstract of: WO2026085256A1
The present disclosure relates to lipids and compositions thereof. In various aspects of the disclosure, the compositions are lipid nanoparticle compositions that are used as adjuvants used with vaccines, such as RNA vaccines, and/or to prevent or treat diseases or disorders in a subject in need thereof.
Absstract of: US20260108536A1
Aspects of the disclosure relate to a composition and methods for treating breast cancer using a cannabinoid-based nanoplatform. The composition comprises phytocannabinoids, including THC, CBD, CBG, and CBC, incorporated into nanoparticles for enhanced bioavailability and controlled release. The method involves administering the composition to patients with breast cancer, particularly stages I and II, to inhibit VEGF pathways and induce apoptosis. The treatment targets estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), HER2-positive, and triple-negative breast cancers. Aspects of the disclosure further provide the production of the composition using nano emulsification techniques to create nanoparticles smaller than 200 nm. This composition offers a novel, targeted approach to reducing tumor growth and metastasis in breast cancer patients.
Nº publicación: AU2024362372A1 23/04/2026
Applicant:
PNASEER INC
Absstract of: AU2024362372A1
When a biological material sensitive to an external reaction is incorporated during hydrogel production, physical stimulation or chemical stimulation applied in conventional hydrogel production methods requires a sophisticated process and can affect the activity and structure of particles in the hydrogel. On the other hand, a hydrogel using an aqueous-two phase system and a method for producing same provided by the present invention can simultaneously achieve hydrogel formation and the encapsulation of desired nanoparticles in the hydrogel. The present invention has succeeded in simply concentrating desired nanoparticles in a hydrogel with a high yield. In addition, the present invention relates to a hydrogel using an aqueous-two phase system and a method for producing same, wherein concentration and hydrogel formation are simultaneously performed, and thus the time for producing the hydrogel is reduced and the cost is significantly reduced.
BOPI
Electronic site
